Safety, Tolerability, and Long-Term Clinical Outcomes of an IL-15 analogue (N-803) Admixed with Bacillus Calmette-Guérin (BCG) for the Treatment of Bladder Cancer Jul 7, 2023 | Bladder Cancer
Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2+ pediatric solid tumors and in vivo survival of xenografted immunodeficient NSG mice Jul 7, 2023 | Uncategorized
Combinatorial Natural Killer Cell-based Immunotherapy Approaches Selectively Target Chordoma Cancer Stem Cells Jul 7, 2023 | Uncategorized
Identification and validation of expressed HLA-binding breast cancer neoepitopes for potential use in individualized cancer therapy Jun 29, 2023 | Articles, Breast Cancer
Dual-Antigen COVID-19 Vaccine Subcutaneous Prime Delivery With Oral Boosts Protects NHP Against SARS-CoV-2 Challenge Sep 17, 2021 | COVID-19, SARS-CoV-2